Member Info for OAPK20

Dirty MM’s delaying trade prints. LR’s popping up

Achievable on next 9 assay results or not ?

LR from yesterday

Is someone interested in buying GSCU if they prove a significant resource?

Probably likely prove the resource and get it to a stage to sell rather than JV or go it alone.

What do you think ?

The high-grade Cu-Ag mineralogy type and associated advanced argillic style alteration suggests the lodes at Mostaza are part of a high-sulphidation epithermal system, potentially related to a yet-to-be-discovered porphyry style deposit occurring at depth.

Sam Garrett, Chief Executive Officer of Great Southern Copper, said: "This is a tremendously significant result for both copper and silver. These exceptional and exciting assay grades demonstrate that the former Mostaza mine has the potential to be a high-grade high-value Cu-Ag deposit.

Drill hole CNG25 DD001 was designed specifically to verify the width and grade of mineralisation reported in historical drill hole EDH25, which reported 25.33m of 0.53% Cu. Drill samples for EDH25 were assayed at uncertified local facilities in the early 1980's so it was important to confirm the veracity of these results from the outset. Assay grades for CNG25 DD001 are significantly higher than the historically reported EDH25 results and if this is confirmed in other GSC drillholes, it could have a positive impact on the potential economics of the Mostaza resource.

We are hopeful that the remaining GSC holes at Mostaza will return further exciting results and look forward to updating the market. Planning for the next phase of drilling plus metallurgical test work is already underway."

Great Southern Copper plc

("GSC" or the "Company")

First assays from Cerro Negro return 20m @ 3.3% Cu and 270g/t Ag from 27m depth

Includes 7m @ 5.72% Cu and 490g/t Ag from 31m depth

Great Southern Copper plc (LSE: GSCU), the company focused on copper-gold-lithium exploration in Chile, is pleased to report exceptional first assay results from Phase I drilling at the Mostaza Mine, Cerro Negro.

Highlights:

· Assay results received for hole CNG25 DD001 drilled at the historical Mostaza Mine include:

Ø 20m @ 3.31% Cu, 269.89g/t Ag from 27m depth

Ø Including 7m @ 5.72% Cu, 489.57g/t Ag from 31m depth

Ø Including 3m @ 6.62% Cu, 562.67g/t Ag from 35m depth

· Peak assay grades of 6.79% Cu, 583g/t Ag and 0.35% Sb

· CNG25 DD001 assay grades for Cu and Ag over 600% higher than historical grades reported for adjacent 1980's drillhole EDH251 indicates potential for significant under-reporting of historical assay results

· Strike and depth continuity of visible mineralisation confirmed by GSC drill holes2 with mineralisation open in all directions

· Assay results for remaining Phase I drill holes, CNG25 DD002 - 009, are pending

· Planning for follow-up resource and exploration drilling underway

· GSC holds option to own 100% of the Mostaza mine and Cerro Negro project

· Prospect located at low elevation with excellent access to infrastructure and mining services

#Copper - COMEX Up 17 cents to $4.70 on copper tariff threats

Assay results to come from the lab. Can anyone say how significant the discovery or confirmation of a Porphyry deposit could be for a junior explorer like GSCU.

Https://www.yahoo.com/news/fda-rehires-staff-medical-devices-001509057.html

The Trump administration is reinstating some employees in the Food and Drug Administration's medical devices division after dozens were laid off as part of a government-wide cost-cutting initiative led by billionaire Elon Musk and his Department of Government Efficiency, according to two people familiar with the matter.

Around 180 employees from the FDA's Center for Devices and Radiological Health, including physicians and cybersecurity experts, were let go on Feb. 15, two workers said they were told by their supervisors.

“These people are indispensable,” one said. "Many of these roles require so much training and specialization and are so important for keeping people alive."

“ One source said they believe the majority of the roughly two dozen people who were fired from the cardiac devices unit — which oversees devices such as pacemakers and implantable defibrillators — to come back.

AdvaMed, a trade group for the medical device industry, had pushed back against the job cuts last week, saying in a statement on Feb. 18 that the firings “could have a very negative impact on patient care in this country.”

Medical device makers, similar to drug companies, pay user fees to the FDA to have their products reviewed. One source said there were concerns that the job cuts could delay device approvals by months or years. The time lost by the brief job cuts is already expected to delay some work, the source said.”

Tech it wouldn’t be a surprise if this followed a similar pattern to STX. The Placees will likely flip to anyone trying to average down from the Medicare spike and continue flipping into the volume. GENI even with FDA onside have a journey ahead to get Docors to push this to patients. It’s whether £4.1M is sufficient to get that traction and growth in the coming months.

20p Tech. Bit punchy. Retail uptake as bad or worse than the last one. Got £4.1M in the end though. Just the big FDA Pump to come.

The Company confirms that the Retail Offer closed at 5.00 p.m. on 17 February 2025 and that it has received conditional subscriptions for 1,809,508 new Ordinary Shares at the Issue Price of 3.7 pence per share in the Retail Offer.

In addition, the Company intends to carry out a separate retail offer of up to 13,513,514 new Ordinary Shares

What do you think of the numbers GENI have projected Tech 🥴

Hi Tech. Just the FDA pump to come. Might get lower than placing again though. See what the uptake is and how busy Oberon get

More likely now at lower price so run up to FDA approval can be pumped and dumped, whether it’s given or not.

Think a few are smarting from the recent spike and dump

Est - 298,586,048 shares in issue after dilution if there’s a full uptake.

Similar to STX. IF they get the uptake. Approval Q2 now. If it ever comes.

T he Company's submission has completed FDA substantive review (July 2024) and following further discussions with the FDA is expected to progress to approval in early Q2 2025. FDA approval of CARDIO inCode would enable the test to be provided as a medical device (kit) format which the directors expect would substantially expand the market for the test.

In January 2025, the Company announced that its CARDIO inCode test had been included in the U.S. Centres for Medicare and Medicaid Services (CMS) 2025 Clinical Lab Fee Schedule with a median price of approximately $500 per test. This development is an important step in facilitating reimbursement from Medicare and Medicaid across the United States. In addition, the Company is preparing a MolDx submission for US state-based reimbursement following receipt of FDA approval.

LIPID inCode has an average reimbursement of $1,229, reflecting the Clinical Laboratory Fee Schedule for the test and the broad Familial Hypercholesterolemia Panel of tests to identify FH genetic variants.

In assessing the future financial drivers of the business, the Company has made the following assumptions about revenues:

· In the US, LIPID inCode is expected to reach on average 100 tests per month by mid 2025, increasing to 275 tests per month by mid 2026, and sold at circa £625 each (blended price of Insurance and self-pay). CARDIO inCode tests are expected to reach on average 120 tests per month from mid 2025 (post FDA-approval), increasing to 250 tests per month by mid 2026 and sold at circa £300 each (blended price of distributor and self-pay).

· In the UK, the Company estimates that each new NHS region would add approximately £650k of revenue annually and assumes the addition of one new region expected in 2025 and two more in 2026.

· In addition, in Spain, the Company expects the launch of CARDIO inCode Public Health and a new partnership would add £400k in each of 2025 and 2026 on top of the normalised 20% annual organic growth.

There’s the dumps. How many more